ImmunityBio Faces Class Action Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation, indicating potential legal risks that may undermine shareholder confidence in the company.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, which underscores the firm's expertise and experience in such cases, potentially influencing the outcome positively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.200
Low
5.00
Averages
7.33
High
9.00
Current: 8.200
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, and missing this date may affect their rights to claim.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is facing legal challenges, and the investigation by Faruq & Faruqi aims to assist investors in understanding their rights and potential legal avenues in this case.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, indicating potential legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, underscoring its commitment to protecting investor rights and its expertise in the legal field.
See More
ImmunityBio Launches Anktiva in Saudi Arabia
- Market Expansion: ImmunityBio's immunotherapy Anktiva has officially launched in Saudi Arabia just two months after partnering with Biopharma and Cigalah Healthcare, marking a significant step in its global expansion and expected to substantially increase the company's market share in the MENA region.
- Sales Growth: Anktiva's unit sales volume surged 168% year-on-year in Q1 2026, driving preliminary net product revenue to $44.2 million, which represents a staggering 700% increase from the full-year 2025 revenue of $113 million, indicating strong market demand and product acceptance.
- Regulatory Approvals: Anktiva has received approval in five regulatory jurisdictions covering 34 countries, including the Saudi Food and Drug Authority's approval in January 2026, further solidifying its legitimacy and competitiveness in the global market.
- Investor Sentiment: Following the announcement, ImmunityBio's stock rose 4% in pre-market trading, reflecting investor optimism about the company's growth potential, while message volumes on Stocktwits increased by over 260% in the past 24 hours, indicating a positive retail investor response.
See More
ANKTIVA Approved for Commercial Use in Saudi Arabia
- Approval Milestone: ANKTIVA (nogapendekin alfa inbakicept) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking a significant strategic expansion for the company in the Middle East market.
- Patient Identification: Initial patients have been identified for ANKTIVA treatment, which not only addresses the urgent need for new cancer therapies in Saudi Arabia but also has the potential to enhance ImmunityBio's market share in the region.
- Partnership Distribution: ANKTIVA is being distributed through partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, ensuring rapid market entry for the product.
- Growing Market Demand: The rapidly increasing cancer burden in the MENA region, particularly the rising incidence of lung and bladder cancers, underscores the urgent need for innovative treatment options, making ANKTIVA's launch timely and critical for patient care.
See More
U.S. Stock Futures Rise Amid Iran Peace Talks and Leadership Changes
- U.S. Stock Futures Rise: Early Tuesday, U.S. stock futures saw a modest increase, with S&P 500 and Nasdaq futures up 0.1% and Dow futures up 0.3%, indicating a potential stabilization in investor sentiment following recent volatility in tech-heavy indices.
- Iran Peace Talks: Reports suggest that Iran may engage in peace talks with the U.S. ahead of a looming ceasefire deadline, although internal resistance from the Revolutionary Guard could complicate these discussions, impacting geopolitical stability in the region.
- Apple Leadership Change: Tim Cook announced his resignation as CEO of Apple, with John Ternus, the current SVP of Hardware Engineering, taking over during a critical period of AI integration, which may influence investor confidence in the company's future direction.
- JPMorgan Raises Year-End Target: JPMorgan has raised its S&P 500 year-end target to 7,600, reflecting a bullish outlook on the market, while traders are also bracing for the upcoming March retail sales data, which could significantly affect market trends.
See More
Anktiva Immunotherapy Research Advances
- Immune Cell Findings: Founder Patrick Soon-Shiong highlighted on social media that low immune cell levels are linked to over a 2-fold increase in breast cancer recurrence risk, reinforcing the scientific rationale for Anktiva and potentially advancing its application in breast cancer treatment.
- Post-COVID Research: Anktiva is currently undergoing a Phase 2 clinical trial to evaluate its efficacy in patients with persistent post-COVID symptoms, aiming to address underlying immune dysfunction by restoring immune cell balance, which could significantly reduce recurrence risk and showcase its potential in new therapeutic areas.
- Cancer Indication Expansion: Approved in 2024 for certain bladder cancer patients, Anktiva is now being studied for multiple cancers including non-small cell lung cancer and pancreatic cancer, indicating its broad indication potential that could lead to new revenue streams for the company.
- Market Sentiment Analysis: While retail sentiment for IBRX remains neutral, the stock has surged over 230% in the past year, reflecting optimistic market expectations for its future developments, particularly in applications for long COVID patients.
See More
Faruqi & Faruqi Encourages Investors to Contact Regarding ImmunityBio Losses
- Legal Action Reminder: Faruq & Faruqi LLP is investigating potential claims against ImmunityBio, particularly for investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting the legal risks they may face.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing contact numbers 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action against ImmunityBio is May 26, 2026, and missing this date may affect their rights to claim.
- Company Background: ImmunityBio, Inc. (NASDAQ: IBRX) is facing legal challenges, and the investigation by Faruq & Faruqi aims to assist investors in understanding their rights and potential legal avenues in this case.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statements Allegation: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant transparency issues within the company.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, indicating potential legal risks that could impact shareholder value.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, underscoring its commitment to protecting investor rights and its expertise in the legal field.
See More
ImmunityBio Launches Anktiva in Saudi Arabia
- Market Expansion: ImmunityBio's immunotherapy Anktiva has officially launched in Saudi Arabia just two months after partnering with Biopharma and Cigalah Healthcare, marking a significant step in its global expansion and expected to substantially increase the company's market share in the MENA region.
- Sales Growth: Anktiva's unit sales volume surged 168% year-on-year in Q1 2026, driving preliminary net product revenue to $44.2 million, which represents a staggering 700% increase from the full-year 2025 revenue of $113 million, indicating strong market demand and product acceptance.
- Regulatory Approvals: Anktiva has received approval in five regulatory jurisdictions covering 34 countries, including the Saudi Food and Drug Authority's approval in January 2026, further solidifying its legitimacy and competitiveness in the global market.
- Investor Sentiment: Following the announcement, ImmunityBio's stock rose 4% in pre-market trading, reflecting investor optimism about the company's growth potential, while message volumes on Stocktwits increased by over 260% in the past 24 hours, indicating a positive retail investor response.
See More
ANKTIVA Approved for Commercial Use in Saudi Arabia
- Approval Milestone: ANKTIVA (nogapendekin alfa inbakicept) has received approval from the Saudi Food and Drug Authority (SFDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer, marking a significant strategic expansion for the company in the Middle East market.
- Patient Identification: Initial patients have been identified for ANKTIVA treatment, which not only addresses the urgent need for new cancer therapies in Saudi Arabia but also has the potential to enhance ImmunityBio's market share in the region.
- Partnership Distribution: ANKTIVA is being distributed through partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution companies in the Middle East, ensuring rapid market entry for the product.
- Growing Market Demand: The rapidly increasing cancer burden in the MENA region, particularly the rising incidence of lung and bladder cancers, underscores the urgent need for innovative treatment options, making ANKTIVA's launch timely and critical for patient care.
See More
U.S. Stock Futures Rise Amid Iran Peace Talks and Leadership Changes
- U.S. Stock Futures Rise: Early Tuesday, U.S. stock futures saw a modest increase, with S&P 500 and Nasdaq futures up 0.1% and Dow futures up 0.3%, indicating a potential stabilization in investor sentiment following recent volatility in tech-heavy indices.
- Iran Peace Talks: Reports suggest that Iran may engage in peace talks with the U.S. ahead of a looming ceasefire deadline, although internal resistance from the Revolutionary Guard could complicate these discussions, impacting geopolitical stability in the region.
- Apple Leadership Change: Tim Cook announced his resignation as CEO of Apple, with John Ternus, the current SVP of Hardware Engineering, taking over during a critical period of AI integration, which may influence investor confidence in the company's future direction.
- JPMorgan Raises Year-End Target: JPMorgan has raised its S&P 500 year-end target to 7,600, reflecting a bullish outlook on the market, while traders are also bracing for the upcoming March retail sales data, which could significantly affect market trends.
See More
